Terminal › Stocks › SAVA

Cassava Sciences, Inc. (SAVA) Stock

Healthcare · Biotechnology · US

$1.32 +40.88%

Last updated Aug 25, 2026 20:18 UTC

SAVA Key Statistics

Market Cap$63.77M

P/E (TTM)-1.52

P/S (TTM)—

P/B (TTM)1.00

Revenue (TTM)$0.00

EPS (TTM)$-0.87

Dividend Yield—

ROE (TTM)-58.78%

Net Margin0.00%

Gross Margin0.00%

52W High$4.98

52W Low$0.86

Analyst ViewBuy

Price Target—

Employees30

Volume134,262

About Cassava Sciences, Inc.

Cassava Sciences, Inc. is a biopharmaceutical enterprise in the clinical development phase, specializing in the creation of treatments for neurodegenerative disorders. The company's primary experimental drug, simufilam, a small-molecule compound, has successfully concluded its Phase 2b clinical trials. In parallel, they are advancing SavaDx, an investigational blood-based biomarker test designed to aid in the detection of Alzheimer's disease. Established in 1998 and headquartered in Austin, Texas, the company underwent a name change in March 2019, previously operating as Pain Therapeutics, Inc.

CEO: Richard Jon Barry. Company website

See SAVA live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open SAVA in Terminal See plans

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corp. MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. ELV Elevance Health Inc.